The world class technology platforms
are enablers for innovation
Biosion's SynAb™ technology is to discover synergistic antibody combinations of two or more monoclonal antibodies to the same drug target, thus achieving maximized clinical efficacy by fully modulating (activating or inhibiting) drug target-mediated disease-associated pathways. Fueled by on our proprietary H³ antibody discovery platform, SynAb™ technology is able to identify synergistic antibody combination to many challenging targets.
The key features of SynAb products for single targets:
- Multiple functional domain targeting
- Superior binding affinity
- Ag-Ab aggregation formation